SCHEMBL5947369

SCHEMBL5947369

Fc1cccc(Oc2cccc(CNCCc3cccc(C(F)(F)F)c3)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.53
▸ ROCK1 Q13464 1/20 0.50
▸ SCN8A Q9UQD0 1/20 0.48
▸ NOS1 P29475 3/20 0.47
▸ NOS3 P29474 1/20 0.47
▸ NOS2 P35228 1/20 0.47
▸ MAPK14 Q16539 1/20 0.46
▸ BCHE P06276 2/20 0.46
▸ LTA4H P09960 1/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ MPO P05164 1/20 0.44
▸ HTR1A P08908 1/20 0.44
▸ DRD2 P14416 1/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ HTR2C P28335 1/20 0.44
▸ HTR7 P34969 1/20 0.44
▸ HTR6 P50406 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947469 0.92 KDM4E (0.62) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947704 0.90 KDM4E (0.69) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947251 0.86 KDM4E (0.61) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947565 0.86 KDM4E (0.61) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947686 0.85 KDM4E (0.60) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947190 0.85 KDM4E (0.60) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947768 0.84 KDM4E (0.59) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947500 0.84 KDM4E (0.59) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947296 0.83 LTA4H (0.62) KDM4EMEN1KMT2ANOS1NOS3
SCHEMBL5947594 0.82 CYP1A2 (0.64) NOS1NOS3NOS2BCHELTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KDM4E 1970/4885MEN1 1889/4885KMT2A 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback